OTCPK:CVSG.F

Stock Analysis Report

Executive Summary

CVS Group plc engages in veterinary, online pharmacy, and retail businesses.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Share Price & News

How has CVS Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

CVSG.F

4.9%

US Healthcare

3.4%

US Market


1 Year Return

n/a

CVSG.F

-9.2%

US Healthcare

5.4%

US Market


Shareholder returns

CVSG.FIndustryMarket
7 Day0%4.9%3.4%
30 Day0%-0.4%-1.0%
90 Dayn/a-5.3%-0.4%
1 Yearn/a-7.8%-9.2%7.7%5.4%
3 Yearn/a31.5%26.2%46.2%36.8%
5 Yearn/a62.7%53.0%65.6%47.5%

Price Volatility Vs. Market

How volatile is CVS Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CVS Group undervalued compared to its fair value and its price relative to the market?

83.74x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: CVSG.F ($7.65) is trading above our estimate of fair value ($6.44)

Significantly Undervalued: CVSG.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CVSG.F is poor value based on its PE Ratio (83.7x) compared to the Healthcare industry average (20.2x).

PE vs Market: CVSG.F is poor value based on its PE Ratio (83.7x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: CVSG.F is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: CVSG.F is overvalued based on its PB Ratio (3.6x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is CVS Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

22.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVSG.F's forecast earnings growth (22.2% per year) is above the savings rate (2.7%).

Earnings vs Market: CVSG.F's earnings (22.2% per year) are forecast to grow faster than the US market (14.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CVSG.F's revenue (2.4% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: CVSG.F's revenue (2.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has CVS Group performed over the past 5 years?

14.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CVSG.F's earnings have grown by 14.9% per year over the past 5 years.

Accelerating Growth: CVSG.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CVSG.F had negative earnings growth (-34.7%) over the past year, making it difficult to compare to the Healthcare industry average (5.3%).


Return on Equity

High ROE: CVSG.F's Return on Equity (4.2%) is considered low.


Return on Assets

ROA vs Industry: CVSG.F's Return on Assets is below or equal to the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: CVSG.F's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is CVS Group's financial position?


Financial Position Analysis

Short Term Liabilities: CVSG.F's short term assets (£74.1M) exceeds its short term liabilities (£65.4M)

Long Term Liabilities: CVSG.F's short term assets (74.1M) do not cover its long term liabilities (155.4M)


Debt to Equity History and Analysis

Debt Level: CVSG.F's debt to equity ratio (83.4%) is considered high

Reducing Debt: CVSG.F's debt to equity ratio has reduced from 129.2% to 83.4% over the past 5 years.

Debt Coverage: CVSG.F's debt is well covered by operating cash flow (23.6%).

Interest Coverage: CVSG.F's interest payments on its debt are well covered by EBIT (3.7x coverage).


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is CVS Group's current dividend yield, its reliability and sustainability?

0.63%

Current Dividend Yield


Dividend Yield vs Market

company0.6%marketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Years0.7%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: CVSG.F's dividend (0.63%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: CVSG.F's dividend (0.63%) is low compared to the top 25% of dividend payers in the US market (3.77%).

Stable Dividend: CVSG.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: CVSG.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CVSG.F is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CVSG.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CVS Group's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Simon Innes (59yo)

15.5yrs

Tenure

UK£487,000

Compensation

Mr. Simon Campbell Innes has been the Chief Executive at CVS Group PLC since January 2004. Mr. Innes serves as the Chief Executive Officer of CVS (UK) Limited. He served as the Chief Executive of Vision Ex ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Simon's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.5yrs

Average Tenure

Experienced Management: CVSG.F's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

1.5yrs

Average Tenure

57yo

Average Age

Experienced Board: CVSG.F's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUK£1,284,80508 Oct 19
Simon Innes
EntityIndividual
Role
Chief Executive Officer
Chief Executive & Executive Director
Shares105,000
Max PriceUK£12.24
BuyUK£52,85631 Jan 19
Richard William Fairman
EntityIndividual
Role
Member of the Board of Directors
Group Finance Director & Director
Shares10,000
Max PriceUK£5.29
BuyUK£49,00231 Jan 19
Simon Innes
EntityIndividual
Role
Chief Executive Officer
Chief Executive & Executive Director
Shares10,000
Max PriceUK£4.90
BuyUK£103,13931 Jan 19
Richard Connell
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares20,000
Max PriceUK£5.32
BuyUK£78,53106 Dec 18
Richard Connell
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares10,000
Max PriceUK£7.85
BuyUK£12,03004 Dec 18
Richard William Fairman
EntityIndividual
Role
Member of the Board of Directors
Group Finance Director & Director
Shares1,450
Max PriceUK£8.30

Ownership Breakdown


Management Team

  • Simon Innes (59yo)

    Chief Executive & Executive Director

    • Tenure: 15.5yrs
    • Compensation: UK£487.00k
  • Gordon Palmer

    Head of IT

    • Tenure: 0yrs
  • Zak Leavold

    Commercial Director

    • Tenure: 1.5yrs
  • John Innes

    Referral Director

    • Tenure: 0yrs
  • James Kennedy

    CVS Farm Animal Director

    • Tenure: 1.4yrs
  • Ben Jacklin

    Small Animal Operations Director & Member of Equine Clinical Advisory Committee

    • Tenure: 3.5yrs
  • Richard Killen

    Director of Clinical Services

    • Tenure: 2.9yrs
  • Robert Dawson

    Small Animal Director

    • Tenure: 2.9yrs
  • Richard William Fairman (51yo)

    Group Finance Director & Director

    • Tenure: 0.9yrs
  • Joe Williams

    Small Animal Veterinary Director & Chair of Clinical Advisory Committee

    • Tenure: 1.5yrs

Board Members

  • Deborah Kemp (57yo)

    Non Executive Director

    • Tenure: 1.5yrs
    • Compensation: UK£23.00k
  • Richard Connell (64yo)

    Non-Executive Chairman

    • Tenure: 0yrs
    • Compensation: UK£113.00k
  • Simon Innes (59yo)

    Chief Executive & Executive Director

    • Tenure: 15.5yrs
    • Compensation: UK£487.00k
  • Mike McCollum (51yo)

    Senior Independent Non-Executive Director

    • Tenure: 0yrs
    • Compensation: UK£46.00k
  • David Langrish

    Member of Equine Clinical Advisory Committee

    • Tenure: 3.3yrs
  • Ben Jacklin

    Small Animal Operations Director & Member of Equine Clinical Advisory Committee

    • Tenure: 3.5yrs
  • Richard William Fairman (51yo)

    Group Finance Director & Director

    • Tenure: 0.9yrs
  • Joe Williams

    Small Animal Veterinary Director & Chair of Clinical Advisory Committee

    • Tenure: 1.5yrs

Company Information

CVS Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CVS Group plc
  • Ticker: CVSG.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: UK£558.949m
  • Listing Market Cap: UK£702.100m
  • Shares outstanding: 70.44m
  • Website: https://www.cvsukltd.co.uk

Number of Employees


Location

  • CVS Group plc
  • CVS House
  • Owen Road
  • Diss
  • Norfolk
  • IP22 4ER
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CVSGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2007
4C9DB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2007
CVSG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2007

Biography

CVS Group plc engages in veterinary, online pharmacy, and retail businesses. The company operates through four segments: Veterinary Practice, Laboratory, Crematoria, and Animed Direct. It operates animal v ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/13 01:40
End of Day Share Price2019/04/15 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.